Author:
Rhodes Anthony,Jasani Bharat,Couturier Jérôme,McKinley Mark J.,Morgan John M.,Dodson Andrew R.,Navabi Hossein,Miller Keith D.,Balaton André J.
Publisher
Oxford University Press (OUP)
Reference34 articles.
1. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659-2671.
2. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (Her2+/MBC) markedly increases anticancer activity: a randomised multinational controlled phase III trial [abstract]. Proc Am Soc Clin Oncol. 1998;17:98A. Abstract 377.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
4. Wisecarver JL. HER-2/neu testing comes of age [editorial]. Am J Clin Pathol. 1999;111:299-301.
5. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol. 2000;113:171-175.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献